dom.einhorn01's  Instablog

Send Message
  • U.S. Will Still Lead Global Market In Migraine Treatments By 2023 0 comments
    Jun 25, 2014 10:27 PM | about stocks: PSHR

    The United States will still lead the global market when it comes to migraine treatment through 2023, Herald Online reported as the nation celebrates the month of June as National Migraine Awareness Month. In the U.S., over 35 million people are suffering from migraines.

    (click to enlarge)

    Pharmapoint Research and Market reported the U.S. has a 77 percent global share of the migraine treatment market and will keep its lead through year 2023, increasing its share to 84 percent. France, Germany, Italy, the UK, and Japan are among the major global market of migraine treatment and drugs.

    Due to a large population of migraine sufferers and a high drug price, the U.S. will continue to dominate the market compared to other major markets around the globe. The research added despite new treatment, drugs currently offered in the marketplace will still be saleable. Generic drugs, existing branded products and new classes of migraine therapy classes will affect the market sales during the forecasted period. It added, the use of botox for chronic migraine will be expanding and mature products reformulations by 2023.

    However generic drugs in the market could affect the sales of branded migraine drugs, the research added.

    Worldwide, migraine treatment and drug markets generate at least $2 billion in annual sales and is expected to climb to $3.7 billion by 2023. The research added that there are several new drugs and therapy classes to be launched, contributing to the increase in revenues.

    Out of the millions of migraine sufferers, about three million are chronic and 13 percent of the populations who have migraines are adults. In coming up with the data, the researchers covered key topics such as unmet needs, research and development clinical trial assessments, and analysis of migraine therapy markets.

    Dr. Dennis Lipton, internal medicine specialist at Vail Valley Medical Center in Colorado gave some pointers about migraine. He said that there is a need to distinguish between headache and migraine.

    "My job as a physician is to make this important differentiation and ensure that a headache does not represent something more worrisome," Lipton was quoted as saying . "That's why, if someone has a new, changed or otherwise unexplained headache, it's important to get it evaluated. Many people with disruptive headaches that don't respond well to over-the-counter medications have diagnosed themselves with chronic sinus problems, eye strain or tension headache. They may actually meet criteria for migraine and are missing out on effective treatments."

    There are several medications prescribed for the migraine sufferer, they are propranolol, verapamil, and topiramate. For simple headaches, there is always the ever reliable acetaminophen or ibuprofen. But not all headaches need medication. Sometimes a cold compress, heat therapy, massage or exercise can also help.

    Pacific Shore Holdings Inc. (PSHR) manufacturer of an effective pain reliever, brings to the consumers the new Thermal-Aid Headache Relief System. The system provides complete relief for migraine and tension headache sufferers. The system includes a clinically proven headache relief cream and a specially designed cold compress eye pack. The Thermal-Aid line is comprised of several heating and cooling therapy packs that come in various sizes, for adults and children.

    Stocks: PSHR
Back To dom.einhorn01's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.